Imagine RNA medicines are like precious letters that need to reach a specific house, but they usually get destroyed or lost in the mail. This technology creates a smart, biodegradable envelope made of peptides that protects the letter and ensures it reaches the right organ, like the heart or lungs. Unlike current fatty envelopes that mostly end up in the liver, these are easier to make and safer for the body.
Current RNA delivery methods (viral and lipid nanoparticles) suffer from toxicity, high production costs, and a tendency to accumulate in the liver, limiting their use for other organs.
A modular platform of biodegradable, non-immunogenic peptide carriers and an AI-enhanced predictive model for vehicle design.
If you are an RNA therapeutics developer dealing with the 'delivery problem' where naked RNA is degraded by endonucleases — this project developed peptide carriers that protect the cargo and deliver it to the cytosol. This allows for the targeting of organs beyond the liver, such as the spleen and heart.
If you are a cancer immunotherapy firm dealing with the toxic side-effects of viral or lipid nanoparticle vectors — this project developed non-immunogenic peptide carriers. These biodegradable vehicles reduce toxicity and can be used for a proprietary flagship RNA-based immunotherapy.
If you are a rare disease biotech dealing with the high cost and complexity of treating 36 million Europeans with genetic diseases — this project developed a modular, automated production platform for carriers. This reduces production costs and accelerates the development of new carriers through AI-enhanced predictive design.
Based on available project data, the production of these peptide carriers is described as simple, cheap, and capable of being automated.
Yes, the project emphasizes that production is automated and simple, and it aims to validate vehicles in industrially relevant contexts.
The project aims to launch a company that will develop both internal and external therapeutic pipelines using their proprietary flagship RNA-based immunotherapy and customized carriers.
The project is working to establish a strong Chemistry, Manufacturing and Control (CMC) package early on to meet regulatory requirements.
The project period runs from 2023-06-01 to 2026-05-31, with the goal of advancing to the preclinical trial stage.
The project is currently led by a single academic partner, the Universidad de Santiago de Compostela (ES). With 0 industry partners and a 0% industry ratio, the current structure is purely university-driven, though the stated objective is to spin off a commercial company to manage therapeutic pipelines.
Contact the research office at Universidad de Santiago de Compostela
Contact us to facilitate a partnership with the Universidad de Santiago de Compostela for RNA delivery licensing.
